Aggregopathy in neurodegenerative diseases:: Mechanisms and therapeutic implication

被引：42
作者：
Dohm, C. P. [1 ]
Kermer, P.
Baehr, M.
机构：
[1] Univ Hosp Gottingen, Dept Neurol, Gottingen, Germany
来源：
NEURODEGENERATIVE DISEASES | 2008年 / 5卷 / 06期
关键词：
aggregopathy; neurodegeneration; Parkinson's disease; neuroprotection; ubiquitin-proteasome system; therapeutic approaches; alpha-synuclein;
D O I：
10.1159/000119459
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Many neurodegenerative diseases such as Parkinson's, Alzheimer's, Huntington's and Lou Gehrig's disease are associated with the misfolding and aggregation of proteins. While the relevance of these aggregates for neuronal degeneration and their impact on cellular function is still a matter of debate, several experimental therapeutic approaches have been aimed at interfering with protein aggregation. In this review, we want to summarize the current understanding of aggregate formation and toxicity in neurodegenerative diseases with an emphasis on Parkinson's disease. Furthermore, we will discuss current treatment strategies in these diseases targeting aggregate formation and concurrent neuronal cell death in these diseases. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码：321 / 338
页数：18
相关论文
共 207 条
[1]   A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe [J].
Abbas, N ;
Lücking, CB ;
Ricard, S ;
Dürr, A ;
Bonifati, V ;
De Michele, G ;
Bouley, S ;
Vaughan, JR ;
Gasser, T ;
Marconi, R ;
Broussolle, E ;
Brefel-Courbon, C ;
Harhangi, BS ;
Oostra, AB ;
Fabrizio, E ;
Böhme, GA ;
Pradier, L ;
Wood, NW ;
Filla, A ;
Meco, G ;
Denefle, P ;
Agid, Y ;
Brice, A .
HUMAN MOLECULAR GENETICS, 1999, 8 (04) :567-574
[2]   Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system [J].
Abeliovich, A ;
Schmitz, Y ;
Fariñas, I ;
Choi-Lundberg, D ;
Ho, WH ;
Castillo, PE ;
Shinsky, N ;
Verdugo, JMG ;
Armanini, M ;
Ryan, A ;
Hynes, M ;
Phillips, H ;
Sulzer, D ;
Rosenthal, A .
NEURON, 2000, 25 (01) :239-252
[3]   CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation [J].
Al-Ramahi, Ismael ;
Lam, Yung C. ;
Chen, Hung-Kai ;
de Gouyon, Beatrice ;
Zhang, Minghang ;
Perez, Alma M. ;
Branco, Joana ;
de Haro, Maria ;
Patterson, Cam ;
Zoghbi, Huda Y. ;
Botas, Juan .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (36) :26714-26724
[4]   Ubiquitin, cellular inclusions and their role in neurodegeneration [J].
Alves-Rodrigues, A ;
Gregori, L ;
Figueiredo-Pereira, ME .
TRENDS IN NEUROSCIENCES, 1998, 21 (12) :516-520
[5]   Inhibitors of α-synuclein oligomerization and toxicity:: a future therapeutic strategy for Parkinson's disease and related disorders [J].
Amer, Dena A. M. ;
Irvine, G. Brent ;
El-Agnaf, Omar M. A. .
EXPERIMENTAL BRAIN RESEARCH, 2006, 173 (02) :223-233
[6]   Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease [J].
Anderson, John P. ;
Walker, Donald E. ;
Goldstein, Jason M. ;
de laat, Rian ;
Banducci, Kelly ;
Caccavello, Russell J. ;
Barbour, Robin ;
Huang, Jiping ;
Kling, Kristin ;
Lee, Michael ;
Diep, Linnea ;
Keim, Pamela S. ;
Shen, Xiaofeng ;
Chataway, Tim ;
Schlossmacher, Michael G. ;
Seubert, Peter ;
Schenk, Dale ;
Sinha, Sukanto ;
Gai, Wei Ping ;
Chilcote, Tamie J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (40) :29739-29752
[7]  
Andersson E, 2006, CELL, V124, P393, DOI [10.1016/j.cell.2005.10.037, 10.1016/J.CELL.2005.10.037]
[8]  
[Anonymous], 2003, NEUROLOGICAL DISORDE, DOI DOI 10.1016/B978-012125831-3/50220-3
[9]   Mechanisms of suppression of α-synuclein neurotoxicity by geldanamycin in Drosophila [J].
Auluck, PK ;
Meulener, MC ;
Bonini, NM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (04) :2873-2878
[10]   Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease [J].
Auluck, PK ;
Chan, HYE ;
Trojanowski, JQ ;
Lee, VMY ;
Bonini, NM .
SCIENCE, 2002, 295 (5556) :865-868
12345678910